For an approval maybe, but not for EUA. To clarify, I'm imagining LL as part of combination therapy or antibody cocktail such as Misiu suggested in her response. The targets are different and the roles of LL and other antiviral MABs are different. So, to me, the approach doesn't seem any different than combining Remdesivir with REGN-COV2 or convalescent plasma or any of the other combinations that are part of the SOC as a treatment regiment.
The revised guidance today, appears to be recommending smaller, less experienced biotechs to collaborate with larger ones for scalability. Therefore, I'm thinking that having one firm manufacture the cocktail is easier and a much more efficient use of the supply chain.
ALL IMO.
Market Data 
Markets 
AI
